Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin‐converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)‐Added trial
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
AbstractBackground:The efficacy and safety of adding an angiotensin receptor blocker (ARB) in heart failure (HF) patients already taking an angiotensin‐converting enzyme‐inhibitor (ACE‐I) plus an aldosterone antagonist is uncertain (especially if taking a beta blocker as well). The CHARM‐Added trial describes the largest experience of using multiple inhibitors of the renin–angiotensin–aldosterone system (RAAS) together.Methods and results:2548 HF patients, taking an ACE‐I (936 no spironolactone/no beta blocker; 1175 no spironolactone/beta blocker; 199 spironolactone/no beta blocker; 238 sprionolactone/beta blocker), were randomized to placebo or candesartan and followed for 41 months (median). The primary outcome was cardiovascular death or HF hospitalization. In patients taking both a beta blocker and spironolactone (in addition to an ACE‐I) at baseline, the candesartan:placebo hazard ratio was 0.85(95% CI 0.56, 1.29), compared to 0.85(95% CI 0.75, 0.96) in all randomized patients (interaction p value 0.49).The relative risk of discontinuation of candesartan (compared to placebo) because of hypotension, increased serum creatinine or hyperkalemia was not increased in patients taking spironolactone at baseline.Conclusions:An ARB may provide added benefit, at acceptable risk, in HF patients already taking spironolactone as well as an ACE‐I and beta blocker. These findings must be confirmed in a prospective randomized trial before this approach can be recommended, routinely.
